SCHEMBL24744896

SCHEMBL24744896

COC(=O)c1cc(Br)cc2c1nc(C)n2CC(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 3/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
CACNA1B Q00975 1/20 0.35
PTGER4 P35408 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TLR7 Q9NYK1 1/20 0.34
DCTPP1 Q9H773 1/20 0.34
FPR2 P25090 2/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
GAA P10253 1/20 0.32
PKN1 Q16512 1/20 0.32
PKN2 Q16513 1/20 0.32
ATR Q13535 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24745449 0.89 CACNA1B (0.40) KDM4EALDH1A1MAPTCACNA1BPTGER4
SCHEMBL24744906 0.89 KDM4E (0.37) KDM4EALDH1A1MAPTPOLBHTT
SCHEMBL24745728 0.88 ALDH1A1 (0.37) KDM4EALDH1A1MAPTCACNA1BNPC1
SCHEMBL24745413 0.87 BRD4 (0.38) KDM4EALDH1A1MAPTPOLBHTT
SCHEMBL24745532 0.87 DCTPP1 (0.38) KDM4EALDH1A1MAPTCACNA1BNPC1
SCHEMBL24745467 0.87 ALDH1A1 (0.37) KDM4EALDH1A1MAPTCACNA1BNPC1
SCHEMBL24746772 0.82 PTGER4 (0.40) KDM4EPTGER4TLR7DCTPP1
SCHEMBL24745446 0.82 TLR7 (0.35) KDM4EALDH1A1MAPTCACNA1BNPC1
SCHEMBL24744762 0.82 PKN1 (0.47) KDM4EALDH1A1MAPTPTGER4SMN1; SMN2
SCHEMBL29893726 0.82 PKN1 (0.47) KDM4EALDH1A1MAPTPTGER4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 US disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 CN disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP KDM4E 1943/4885ALDH1A1 956/4885MAPT 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.